Objective to evaluate the effect of laparoscopic radical cystectomy for 32 cases of bladder cancer. Methods 64 patients with bladder cancer admitted from March 2017 to November 2019 in our hospital were divided into laparoscopic group (laparoscopic radical cystectomy) and open group (open radical cure) according to different surgical treatment methods Cystectomy (32 cases). Observe and compare the perioperative indexes, incidence of postoperative complications, postoperative bladder function indexes and pain scores of the two groups. Results The laparoscopic group had shorter operation time and hospital stay, lower intraoperative blood loss and postoperative pain score, postoperative exhaust time to restore eating time, shorter intestinal function recovery time, and lower postoperative complication rate, and The control group had statistical difference (p <0.05). Conclusion The laparoscopic radical cystectomy for bladder cancer patients has shorter operation time and less intraoperative bleeding, which can reduce the occurrence of postoperative pain and complications. The bladder function recovery of patients is faster and the curative effect is accurate.

Zheng Xiaoqing, Guo Zhenyu, Zheng Hao, Chu Xi, Zheng Chuna. Laparoscopic Radical Cystectomy for 32 Cases of Bladder Cancer. Frontiers in Medical Science Research (2020) Vol. 2 Issue 2: 56-61. https://doi.org/10.25236/FMSR.2020.020210.

[1] Thomas G. Clifford, Behrod Katebian, Christine M. Van Horn, et al (2018). Urinary tract infections following radical cystectomy and urinary diversion: a review of 1133 patients [J]. World Journal of Urology, vol.36, no.50, pp.1-7.
[2] Groeben C, Koch R, Baunacke M, et al (2018). Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014[J]. Annals of Surgical Oncology, vol.12, no.31, pp.1-8.
[3] Younis Johnny S, Shapso Nora, Fleming Richard,et al (2019). Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: a systematic review and meta-analysis [J]. Human Reproduction Update, vol.32, no.3, pp.3-4.
[4] Shao-ling Yang, Ji-jiao Wang, Ming Chen,et al (2018). Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study [J]. International Journal of Medical Sciences, vol.15, no.3, pp.228-237.
[5] Huilin Tang, Weilong Shi, Shuangshuang Fu,et al (2018). Pioglitazone and bladder cancer risk: a systematic review and meta-&shy;analysis [J]. Cancer Medicine, vol.7, no.4, pp.113-114.
[6] Narayan V M, Adejoro O, Schwartz I, et al (2018). The Prevalence and Impact of Urinary Marker Testing in Patients with Bladder Cancer.[J], vol.199, no.1, pp.74.
[7] Wong MCS, Fung FDH, Leung C, et al (2018). The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection [J]. Sci Rep, vol. 8, no.1, pp.1129.
[8] Xin Sun, Tao Zhang, Qifei Deng, et al (2018). Benzidine Induces Epithelial-Mesenchymal Transition of Human Bladder Cancer Cells through Activation of ERK5 Pathway [J]. Molecules & Cells, vol.41 no.3, pp.188-197.